Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05471843 · ClinicalTrials.gov registry record · Phase 1
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 1 study of Mantle Cell Lymphoma and Refractory Mantle Cell Lymphoma (MCL), sponsored by BeiGene.
- Active
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT05471843: Active Phase 1 study of Mantle Cell Lymphoma and Refractory Mantle Cell Lymphoma (MCL), sponsored by BeiGene.
NCT05471843 is a Phase 1 study of Mantle Cell Lymphoma and Refractory Mantle Cell Lymphoma (MCL) that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 125 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05471843, a Phase 1 study of Mantle Cell Lymphoma and Refractory Mantle Cell Lymphoma (MCL), is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
Conditions Studied
Interventions
- DRUG BGB-11417
Study Locations (20)
Other
- Hospital Aleman - Buenos Aires
- Az Sint Jan Brugge - Bruges
- Universitair Ziekenhuis Gent - Ghent
- University Hospitals Leuven - Leuven
- AZ DELTA - Roeselare
- Hospital Erasto Gaertner - Curitiba
- Hospital Mae de Deus - Porto Alegre
Maryland
- Luminis Health Anne Arundel Medical Center - Annapolis
- Maryland Oncology Hematology, Pa - Columbia
Alabama
- University of Alabama At Birmingham Hospital - Birmingham
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Iowa
- Des Moines Oncology Research Association - Des Moines
Louisiana
- Tulane Cancer Center - New Orleans
Missouri
- University of Missouri Hospital, Ellis Fischel Cancer Center - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-09-05 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
What the registry record for NCT05471843 still lists
NCT05471843 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (21% higher).
The record links to 3 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which BGB-11417 is the first listed.
NCT05471843 names 20 study sites across 13 states, led by Other, Maryland, Alabama.
Frequently Asked Questions
What is clinical trial NCT05471843 about?
NCT05471843 is a clinical study titled "Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma". The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monothe...
What is the current status of trial NCT05471843?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2022-09-05. Estimated completion is 2027-01-31.
What conditions does trial NCT05471843 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma.
What interventions are being tested in trial NCT05471843?
The interventions under investigation include: BGB-11417 (DRUG).
Who is sponsoring clinical trial NCT05471843?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05471843 being conducted?
This trial has 20 study locations across Alabama, District of Columbia, Indiana, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05471843's enrollment target sits among peer trials
125 25th of 102 higher than 78 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI